A prospective, parallel group, randomized clinical trial in 60 patients hospitalized with the primary diagnosis of AECOPD or acute respiratory failure with a secondary diagnosis of COPD (ICD-10 codes J44.1 and J96 - J96.2 with J44.9).~The plan is to:~Administer standard bronchodilator protocol with nebulized Albuterol and Ipratropium every 6 hours (n=30)~versus~Nebulized Revefenacin 175 μg once per day and Formoterol 20 μg twice per day (n=30) for up to 7 days of treatment. Study medication will be administered by standard jet nebulizers in both groups.~Investigators will:~Collect the Borg dyspnea scale twice a day during hospitalization~Record the total doses of bronchodilators per day received by each patient~Record the number of rescue doses needed per day of hospital stay~Record the lowest level of FiO2 employed on days 1, 3 and 7 of hospital stay~Record all adverse events and concurrent medications~Investigators will collect:~Physical Exam (Day 1, 3, 7, or ET) Serum Chemistry (Day 1, 3, 7, or ET) Hematology (Day 1, 3, 7, or ET) Chest X-Ray (Day 1).
The purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized Albuterol and Ipratropium.